Marisa Wexler, MS,  senior science writer—

ART-123 (thrombomodulin alfa) failed to prolong the survival of patients with idiopathic pulmonary fibrosis (IPF) who have acute exacerbations, a study found. The study, “Thrombomodulin alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Randomized, Double-blind, Placebo-controlled Trial,” was published in the American…

Hepion Pharmaceuticals‘ CRV431 lowers the production of fibrosis-associated proteins in a variety of cell types, including lung cells, new data from the company show. CRV431 is a small molecule being developed as an investigational treatment for non-alcoholic steatohepatitis (NASH) and viral hepatitis-induced liver disease. Both of these conditions are…

A new technique to create lung cells from other, more easily accessible cell types could be useful for understanding diseases like idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). The technique was described in an article, “Reconstructed Single-Cell Fate Trajectories Define Lineage Plasticity…

Galapagos NV announced that its Phase 2 PINTA trial, evaluating the safety and effectiveness of oral GLPG1205 in people with idiopathic pulmonary fibrosis (IPF), has completed patient recruitment ahead of schedule. GLPG1205 is a small molecule designed to specifically block the activity of GPR84, a protein that…

Use of INOpulse — inhaled nitric oxide — increased physical activity and improved patient-reported outcomes in people with pulmonary fibrosis (PF) who are at risk of pulmonary hypertension (PH), new topline clinical trial data suggest. INOpulse, developed by Bellerophon Therapeutics, is a device that delivers nitric oxide (NO)…

The molecular clockwork that regulates circadian rhythms can become dysregulated in the lungs of people with pulmonary fibrosis, promoting processes that scar lung tissue, a study suggests. Poor sleeping habits also appear to upset the lungs’ circadian clockwork, with people who regularly sleep few or excessive hours being more likely…

The Canadian Registry for Pulmonary Fibrosis (CARE-PF) enrolled in its first 18 months more than 1,200 people with interstitial lung disease (ILD), with more than half having either idiopathic pulmonary fibrosis (IPF) or connective tissue disease-associated interstitial lung disease (CTD-ILD). Data collected through the CARE-PF registry could be useful…

Delays in diagnosis and difficulty getting timely access to appropriate specialist care and treatment were highlighted as major gaps in care in a recent survey of people with pulmonary fibrosis (PF) and their healthcare providers. The survey results were discussed in the journal ERJ Open Research in a study,…

Ofev (nintedanib) slows the rate of decline in lung function in people with interstitial lung diseases (ILDs) associated with autoimmune diseases, a new analysis of data from a Phase 3 clinical trial suggests. Ofev is an anti-fibrotic therapy — a medication that lessens tissue scarring — that is already…

The Pulmonary Fibrosis Foundation (PFF) announced a research initiative that aims to expand precision medicine strategies for diagnosing and treating idiopathic pulmonary fibrosis (IPF). The study, called PRECISIONS (for Prospective tReatment EffiCacy in IPF uSIng genOtype for Nac Selection), is being funded by a $22 million grant from the National Institutes of Health and …